Free Trial

Best Stocks Under $5 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $5.00 (5 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Birchcliff Energy stock logo

1. Birchcliff Energy OTCMKTS:BIREF

$4.30 +0.08 (+1.92%)
As of 02:26 PM Eastern

Birchcliff Energy Ltd., an intermediate oil and natural gas company, explores for, develops, and produces natural gas, light oil, condensate, and other natural gas liquids in Western Canada. More about Birchcliff Energy

Market Capitalization
$1.17 billion
P/E Ratio
22.62
Consensus Rating
Strong Buy
Volume
9,229 shares
Average Volume
75,482 shares
Today's Range
$4.21
$4.30
Senseonics stock logo

2. Senseonics NYSE:SENS

$0.46 -0.01 (-2.00%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. More about Senseonics

Market Capitalization
$374.75 million
P/E Ratio
-3.54
Consensus Rating
Buy
Consensus Price Target
$1.54 (+234.2% Upside)
Volume
10.16 million shares
Average Volume
8.16 million shares
Ultrapar Participacoes stock logo

3. Ultrapar Participacoes NYSE:UGP

$4.04 +0.22 (+5.61%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ultrapar Participações SA, through its subsidiaries, operates in the energy and infrastructure business in Brazil. The company distributes liquefied petroleum gas to residential, commercial, and industrial consumers, in addition to renewable electricity and compressed natural gas. More about Ultrapar Participacoes

Market Capitalization
$4.51 billion
P/E Ratio
8.99
Consensus Rating
Buy
Consensus Price Target
$4.50 (+11.2% Upside)
Volume
2.60 million shares
Average Volume
1.87 million shares
Western Copper & Gold stock logo

4. Western Copper & Gold NYSE:WRN

$2.28 +0.11 (+5.07%)
As of 02:57 PM Eastern

Western Copper & Gold Corp. operates as an exploration stage company, which engages in the acquisition, exploration, and future development of mineral resource properties. More about Western Copper & Gold

Market Capitalization
$459.77 million
P/E Ratio
-114.00
Consensus Rating
Buy
Consensus Price Target
$4.25 (+86.4% Upside)
Volume
1.86 million shares
Average Volume
436,224 shares
Perspective Therapeutics stock logo

5. Perspective Therapeutics NYSEAMERICAN:CATX

$3.86 +0.40 (+11.38%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More about Perspective Therapeutics

Market Capitalization
$287.02 million
Consensus Rating
Buy
Consensus Price Target
$12.56 (+224.9% Upside)
Volume
778,829 shares
Average Volume
909,910 shares
Today's Range
$3.49
$3.89
Cardiol Therapeutics stock logo

6. Cardiol Therapeutics NASDAQ:CRDL

$1.08 +0.02 (+1.42%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. More about Cardiol Therapeutics

Market Capitalization
$92.39 million
P/E Ratio
-3.16
Consensus Rating
Buy
Consensus Price Target
$8.00 (+644.2% Upside)
Volume
367,735 shares
Average Volume
444,000 shares
Gold Royalty stock logo

7. Gold Royalty NYSE:GROY

$4.04 +0.24 (+6.18%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gold Royalty Corp., a precious metals-focused royalty company, provides financing solutions to the metals and mining industry. More about Gold Royalty

Market Capitalization
$687.85 million
P/E Ratio
-31.04
Consensus Rating
Buy
Consensus Price Target
$4.64 (+14.9% Upside)
Volume
4.00 million shares
Average Volume
1.83 million shares
Marker Therapeutics stock logo

8. Marker Therapeutics NASDAQ:MRKR

$1.08 +0.02 (+1.89%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. More about Marker Therapeutics

Market Capitalization
$13.98 million
P/E Ratio
-0.79
Consensus Rating
Buy
Consensus Price Target
$13.17 (+1,119.1% Upside)
Volume
279,771 shares
Average Volume
755,463 shares
Nano-X Imaging stock logo

9. Nano-X Imaging NASDAQ:NNOX

$4.24 +0.26 (+6.41%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. More about Nano-X Imaging

Market Capitalization
$244.70 million
P/E Ratio
-4.71
Consensus Rating
Buy
Consensus Price Target
$8.50 (+100.7% Upside)
Volume
1.58 million shares
Average Volume
1.68 million shares
Climb Bio stock logo

10. Climb Bio NASDAQ:CLYM

$1.76 +0.12 (+6.97%)
As of 02:58 PM Eastern

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. More about Climb Bio

Market Capitalization
$119.60 million
P/E Ratio
-2.52
Consensus Rating
Buy
Consensus Price Target
$9.25 (+424.1% Upside)
Volume
498,088 shares
Average Volume
380,283 shares
Foghorn Therapeutics stock logo

11. Foghorn Therapeutics NASDAQ:FHTX

$4.51 +0.09 (+2.06%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. More about Foghorn Therapeutics

Market Capitalization
$255.52 million
P/E Ratio
-3.80
Consensus Rating
Buy
Consensus Price Target
$11.00 (+143.8% Upside)
Volume
98,311 shares
Average Volume
127,048 shares
Talphera stock logo

12. Talphera NASDAQ:TLPH

$1.38 +0.12 (+9.52%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. More about Talphera

Market Capitalization
$62.64 million
P/E Ratio
-3.43
Consensus Rating
Buy
Consensus Price Target
$5.00 (+262.3% Upside)
Volume
593,108 shares
Average Volume
935,439 shares
Denison Mine stock logo

13. Denison Mine NYSEAMERICAN:DNN

$2.84 -0.02 (-0.53%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Denison Mines Corp. engages in the acquisition, exploration, and development of uranium bearing properties in Canada. Its flagship project is the Wheeler River uranium project covering an area of approximately 300,000 hectares located in the Athabasca Basin region in northern Saskatchewan. More about Denison Mine

Market Capitalization
$2.54 billion
P/E Ratio
-47.25
Consensus Rating
Buy
Consensus Price Target
$2.75 (-3.0% Downside)
Volume
114.26 million shares
Average Volume
79.46 million shares
Ur Energy stock logo

14. Ur Energy NYSEAMERICAN:URG

$1.84 -0.01 (-0.27%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization
$677.54 million
P/E Ratio
-10.85
Consensus Rating
Buy
Consensus Price Target
$2.44 (+32.2% Upside)
Volume
9.22 million shares
Average Volume
5.91 million shares
Vizsla Silver stock logo

15. Vizsla Silver NYSEAMERICAN:VZLA

$4.76 +0.29 (+6.38%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vizsla Silver Corp. engages in the exploration, and development of precious and base metal assets. The company explores for gold, silver, and copper deposits. More about Vizsla Silver

Market Capitalization
$1.62 billion
P/E Ratio
-118.88
Consensus Rating
Buy
Consensus Price Target
$3.25 (-31.7% Downside)
Volume
2.79 million shares
Average Volume
3.10 million shares
Quince Therapeutics stock logo

16. Quince Therapeutics NASDAQ:QNCX

$1.92 +0.14 (+7.81%)
As of 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. More about Quince Therapeutics

Market Capitalization
$103.07 million
P/E Ratio
-1.76
Consensus Rating
Buy
Consensus Price Target
$8.14 (+324.3% Upside)
Volume
433,489 shares
Average Volume
242,901 shares
TriSalus Life Sciences stock logo

17. TriSalus Life Sciences NASDAQ:TLSI

$4.78 -0.01 (-0.10%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. More about TriSalus Life Sciences

Market Capitalization
$238.13 million
P/E Ratio
-4.05
Consensus Rating
Buy
Consensus Price Target
$10.90 (+128.3% Upside)
Volume
143,034 shares
Average Volume
73,011 shares
TuHURA Biosciences stock logo

18. TuHURA Biosciences NASDAQ:HURA

$2.60 +0.10 (+3.80%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. More about TuHURA Biosciences

Market Capitalization
$132.60 million
Consensus Rating
Buy
Consensus Price Target
$12.67 (+388.1% Upside)
Volume
274,946 shares
Average Volume
293,499 shares
Today's Range
$2.47
$2.65
CytomX Therapeutics stock logo

19. CytomX Therapeutics NASDAQ:CTMX

$3.32 -0.02 (-0.45%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. More about CytomX Therapeutics

Market Capitalization
$546.68 million
P/E Ratio
5.92
Consensus Rating
Buy
Consensus Price Target
$5.42 (+63.4% Upside)
Volume
1.83 million shares
Average Volume
3.36 million shares
Compass Therapeutics stock logo

20. Compass Therapeutics NASDAQ:CMPX

$3.80 +0.19 (+5.18%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass Therapeutics

Market Capitalization
$527.54 million
P/E Ratio
-8.48
Consensus Rating
Moderate Buy
Consensus Price Target
$13.10 (+245.0% Upside)
Volume
1.26 million shares
Average Volume
1.41 million shares
Biomea Fusion stock logo

21. Biomea Fusion NASDAQ:BMEA

$1.70 -0.15 (-7.84%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea Fusion

Market Capitalization
$101.11 million
P/E Ratio
-0.56
Consensus Rating
Moderate Buy
Consensus Price Target
$9.50 (+457.2% Upside)
Volume
5.71 million shares
Average Volume
1.44 million shares
Aclaris Therapeutics stock logo

22. Aclaris Therapeutics NASDAQ:ACRS

$1.88 +0.04 (+1.90%)
As of 03:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. More about Aclaris Therapeutics

Market Capitalization
$203.12 million
P/E Ratio
-1.37
Consensus Rating
Moderate Buy
Consensus Price Target
$8.71 (+364.8% Upside)
Volume
608,310 shares
Average Volume
971,941 shares
ProQR Therapeutics stock logo

23. ProQR Therapeutics NASDAQ:PRQR

$2.35 +0.08 (+3.35%)
As of 03:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. More about ProQR Therapeutics

Market Capitalization
$245.77 million
P/E Ratio
-5.08
Consensus Rating
Moderate Buy
Consensus Price Target
$8.00 (+241.0% Upside)
Volume
334,827 shares
Average Volume
416,078 shares
Context Therapeutics stock logo

24. Context Therapeutics NASDAQ:CNTX

$1.18 +0.05 (+4.42%)
As of 03:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context Therapeutics

Market Capitalization
$105.85 million
P/E Ratio
-3.28
Consensus Rating
Moderate Buy
Consensus Price Target
$5.20 (+340.7% Upside)
Volume
200,161 shares
Average Volume
201,705 shares
Alumis stock logo

25. Alumis NASDAQ:ALMS

$4.57 +0.06 (+1.29%)
As of 03:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. More about Alumis

Market Capitalization
$471.91 million
Consensus Rating
Moderate Buy
Consensus Price Target
$20.17 (+341.5% Upside)
Volume
562,292 shares
Average Volume
686,868 shares
Today's Range
$4.39
$4.67